News & Events

News, industry insights and noteworthy events.

At Tanner, we take pride in the success of our partnerships and acknowledge the milestones achieved in pursuing our mission; to improve lives by increasing access to medicines around the world.

For media or press inquiries, please email us.

Contact Us

All Articles

  1. Tanner Pharma Group Announces New EVP of Technical Operations

    CHARLOTTE, N.C.–(BUSINESS WIRE)–Tanner Pharma Group (“Tanner”), a global pharma-solutions provider, today announced the hiring of Lee Holmes as Executive Vice President of Technical Operations. Having worked in the healthcare industry for over 25 years across a wide range of global leadership roles, Lee brings with him a wealth of industry knowledge and experience, offering particularly…

    Read More
  2. Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN®

    July 30, 2021 08:00 AM Irish Standard Time DUBLIN, Ireland and CHARLOTTE, USA – Alimera Sciences Europe Limited (“Alimera”), a wholly owned subsidiary of Alimera Sciences, Inc., and Tanner Pharma UK Limited (“Tanner”) announced today the initiation of a global Named Patient Program for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg for the treatment of…

    Read More
  3. Tanner Pharma Group Gives Donation to Benefit MAP International’s Bringing Children Health Program

    Brunswick, GA, July 30, 2021 – MAP International, a nonprofit health organization whose mission is to provide medicines and health supplies to those in need around the world so that they might experience life to the fullest, recently received a generous donation from Tanner Pharma Group. The donation of over 18,000 units of pharmaceutical products…

    Read More
  4. Building a Culture of Well-Being: A Partnership Between Tanner Pharma Group and Red Dot 365

    At Tanner Pharma, our purpose revolves around people. This focus not only includes the patients, physicians, pharma companies and NGO’s we serve and partner with, but our outstanding team members who help us make a difference and positively impact lives around the world. With that in mind, we are continuously seeking ways to support our…

    Read More
  5. Evolving for the Greater Good in the COVID-19 Era

    At Tanner, we think of giving not only as a duty but as a privilege. A critical part of our success is that the mission and culture of Tanner Pharma is embodied in each member of our team. Whether it’s through the global programs we develop and manage for our clients, or the fundraising we…

    Read More
  6. From Patient Access to Real World Data – Early Access Programs Offer Compelling Results

    What is an EAP? Early Access Programs (EAPs), also referred to as Compassionate Use, Managed Access Programs or Expanded Access Programs, are a pathway by which pharma and biopharmaceutical companies provide investigational new drugs (INDs) to patients with serious conditions. Often, patients have exhausted their approved therapies and cannot participate in a clinical trial. These…

    Read More
  7. Again Life Italia Announces Partnership with Tanner Pharma Group

    CHARLOTTE, N.C., May 27, 2021 — Again Life Italia S.r.l. (“ALI”), a pharmaceutical biotechnology company headquartered in Italy, and TannerLAC UK Limited (“TannerLAC”), a wholly owned subsidiary of Tanner Pharma Group and company leader in the Latin American market, announced today the signing of a business partnership agreement for Latin America.  With a presence in…

    Read More
  8. Epimune and Tanner Pharma Group enter into Distribution Partnership for Latin America

    Berlin, 27 January 2021 – Epimune GmbH, a molecular diagnostic company that develops, manufactures and commercializes in-vitro diagnostic tests for immune cell quantification from a drop of blood, announced today that it has entered into a license agreement with TannerLAC UK Limited (“TannerLAC”), a wholly owned subsidiary of Tanner Pharma Group for the i.Mune TBNK in-vitro…

    Read More
  9. Elevar Therapeutics and Tanner Pharma Group Announce Launch of Global Named Patient Program to Provide Access to Apealea® (paclitaxel micellar)

    SALT LAKE CITY and CHARLOTTE, N.C., Dec. 1, 2020 /PRNewswire/ — Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, and Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, announced today that they have launched a global…

    Read More
  10. Sending Wilson home: A story of perseverance and teamwork

    (Repost from ZNM) Wilson – a small child with a rare muscle condition called centronuclear myopathy – gets life-saving medical equipment and goes home to his family after spending almost 2 years at the hospital thanks to the support of two patient organizations in Europe and US and the financial assistance and guidance from Tanner…

    Read More
  11. 5 Things to Consider When Commercializing a New Drug in Latin America

    Some of the over 8,000 drugs in development are poised to be breakthrough treatments that will substantially improve or save patients’ lives. The pharmaceutical companies developing these revolutionary medications have at least two goals: ensuring their research investment is profitable and making sure the drug is available to help any person who needs it.   If your company is developing a new drug, you may be ready to achieve these goals in your existing or developed markets, but what about new ones, like Latin America and other emerging markets? If you haven’t done it before, that’s an entirely…

    Read More
  12. The Value of Real-World Data from Global Expanded Access Programs for Rare Diseases

    John Lagus, Tanner’s EVP of Business Development focusing on managed access programs, recently spoke at MarketandMarkets’ Digital Event on Orphan Drugs and Rare Diseases about the value of real-world data (RWD) from expanded access programs (EAPs) for rare diseases. Here are a few highlights from his talk.  Years ago, while in Botswana, John Lagus met a woman who offered her life savings to purchase critical medicine for her daughter. This conversation stayed with…

    Read More
  13. 3 Insights for Effective Comparator Sourcing

    Whether you’re a global pharma or a biotech start-up, every clinical trial will entail overcoming challenges with sourcing, packaging, and the logistics of clinical materials. Choosing the right partner provides you with flexibility and risk mitigation, ensuring you can choose the most cost-effective solution, and avoid delays. Here are some of the key factors to…

    Read More
  14. Tanner Pharma Group and Dompé Initiate Distribution Partnership for Oxervate®

    Tanner Pharma Group and Dompé Initiate Distribution Partnership for Oxervate®   MILAN, ITALY and CHARLOTTE, USA – Dompé farmaceutici S.p.A. (“Dompé”) and Tanner Pharma Group, Inc. today announced they have entered into an agreement whereby Tanner Pharma Group will become Dompé’s exclusive distribution partner for Oxervate (cenegermin) in selected countries. The agreement names Tanner Pharma…

    Read More
  15. Elevar Therapeutics and Tanner Pharma Group Announce Global Named Patient Program to Provide Access to Apealea® (micellular paclitaxel)

    SALT LAKE CITY and CHARLOTTE, N.C., July 27, 2020 /PRNewswire/ — Elevar Therapeutics, Inc. (“Elevar”), a late-stage biopharmaceutical company focused on developing and commercializing promising therapies to address unmet needs in cancer, and Tanner Pharma Group (“Tanner”), a global provider of integrated specialty access solutions, today announced a partnership that will facilitate access to Apealea® (micellular paclitaxel) on a named…

    Read More
  16. Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc.

    Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc. May 12, 2020 For Immediate Release Contact: Telephone: 704-552-8407 Email:   CHARLOTTE, N.C. – Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Tasman Pharma Inc. The agreement names Tanner as a…

    Read More
  17. Increasing Access for Rare Disease Patients Globally

    Patients who suffer from rare diseases often lack access to innovative treatment options because the manufacturer of the medicine cannot justify the investment in registering and commercializing the medicine in countries where patient populations are low.  Managed Access Programs provide  manufacturers of innovative medicines for rare diseases a cost-effective option to provide patients access in countries where the medicine is not commercially available.  If a physician chooses to prescribe such…

    Read More
  18. Tanner Pharma Group and Lawley Pharmaceuticals Initiate Global Named Patient Program for AndroFeme® 1

    PERTH, Australia & CHARLOTTE, N.C., June 15, 2020 –-(BUSINESS WIRE)–Lawley Pharmaceuticals and Tanner Pharma Group announced today that they have initiated a global named patient program for AndroFeme® 1 testosterone cream for women. “Partnering with Tanner gives women access to a female specific testosterone treatment for HSDD which is experienced by one in every three…

    Read More

Tanner Pharma Group uses cookies on its website. By continuing to access this website you are agreeing to Tanner Pharma Group’s Data Privacy Policy. For more information, click here.